Latest Articles

Publication Date
All News Scientific
AI Radiomics Accurately Differentiates Endometrial Tumors - Bioengineer.org

AI Radiomics Accurately Differentiates Endometrial Tumors Bioengineer.org

Published: Nov. 4, 2025, 12:27 p.m.
Read Full Article
AI Radiomics Accurately Differentiates Endometrial Tumors - BIOENGINEER.ORG

AI Radiomics Accurately Differentiates Endometrial Tumors BIOENGINEER.ORG

Published: Nov. 4, 2025, 12:27 p.m.
Read Full Article
CT radiomics-based explainable machine learning model for accurate differentiation of malignant and benign endometrial tumors: a two-center study - BioMedical Engineering OnLine

CT radiomics-based explainable machine learning model for accurate differentiation of malignant and benign endometrial tumors: a two-center study BioMedical Engineering OnLine

Published: Nov. 4, 2025, 11:50 a.m.
Read Full Article
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - The Manila Times

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times

Published: Oct. 24, 2025, 3:57 p.m.
Read Full Article
Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis - Cell Communication and Signaling

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis Cell Communication and Signaling

Published: Oct. 24, 2025, 12:50 p.m.
Read Full Article
Roche axes 4 Chugai solid tumor assets in early-phase clearout - Fierce Biotech

Roche axes 4 Chugai solid tumor assets in early-phase clearout Fierce Biotech

Published: Oct. 23, 2025, 8:53 a.m.
Read Full Article
Roche axes 4 Chugai solid tumor assets in early-phase clear-out - Fierce Biotech

Roche axes 4 Chugai solid tumor assets in early-phase clear-out Fierce Biotech

Published: Oct. 23, 2025, 8:53 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - BioSpace

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer BioSpace

Published: Oct. 20, 2025, 4:42 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Lelezard

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Lelezard

Published: Oct. 18, 2025, 12:47 p.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - The AI Journal

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer The AI Journal

Published: Oct. 18, 2025, 10:20 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!